15-Acetoxyscirpen-3,4-diol, also known as **T-2 toxin**, is a mycotoxin produced by certain species of Fusarium fungi. It is a potent **immunotoxic**, **cytotoxic**, and **carcinogenic** compound.
**Why it's important for research:**
* **Understanding mycotoxin contamination:** T-2 toxin is a significant contaminant of various agricultural products, including grains, cereals, and animal feed. Research on T-2 toxin helps to understand its occurrence, distribution, and potential health risks associated with contaminated food.
* **Investigating its effects on human and animal health:** T-2 toxin can cause a range of health problems, including:
* **Immune suppression:** It weakens the immune system, making individuals more susceptible to infections.
* **Gastrointestinal problems:** It can cause vomiting, diarrhea, and abdominal pain.
* **Hematopoietic toxicity:** It affects the bone marrow, leading to a decrease in blood cell production.
* **Neurotoxicity:** It can damage the nervous system, leading to neurological symptoms.
* **Carcinogenesis:** T-2 toxin has been linked to an increased risk of certain types of cancer.
* **Developing countermeasures and treatments:** Research on T-2 toxin aims to develop effective strategies to prevent contamination, mitigate its effects, and find potential treatments for T-2 toxin poisoning.
* **Food safety and security:** Understanding T-2 toxin's impact on food safety is crucial for developing effective measures to ensure the safety of food supply chains and prevent contamination.
* **Biological warfare:** Due to its toxicity, T-2 toxin has been investigated as a potential bioweapon. Research on its effects and potential countermeasures is important for national security.
**Overall, research on 15-acetoxyscirpen-3,4-diol (T-2 toxin) is essential for understanding its impact on human and animal health, developing strategies for food safety, and exploring potential applications in the fields of agriculture, medicine, and national security.**
15-acetoxyscirpen-3,4-diol: hydrolysis product of anguidine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 429922 |
| CHEBI ID | 175144 |
| MeSH ID | M0067335 |
| Synonym |
|---|
| CHEBI:175144 |
| (10,11-dihydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-2-yl)methyl acetate |
| anguidine,4-diol-bl5732) |
| nsc-267030 |
| desacetylanguidine |
| trichothec-9-ene-3,15-triol, 12,13-epoxy-, 15-acetate, (3.alpha.,4.beta.)- |
| trichothec-9-ene-3.alpha.,15-triol, 12,13-epoxy-, 15-acetate |
| nsc267030 |
| 2623-22-5 |
| 15-acetoxyscirpen-3,4-diol |
| 15-acetylscirpenetriol |
| deacetylanguidin |
| 15-o-acetylscirpenetriol |
| monoacetoxyscirpenol |
| nsc 267030 |
| 15-mono-o-acetylscirpenol |
| 15-acetoxyscirpenol |
| 4-deacetylanguidin |
| IRXDUBNENLKYTC-UHFFFAOYSA-N |
| scirp-9-ene-3.alpha.,4.beta.,15-triol, 12,13-epoxy-, 15-acetate |
| (3.alpha.)-12,13-epoxytrichothec-9-ene-3,4,15-triol 15-acetate |
| trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 15-acetate, (3.alpha.,4.beta.)- |
| trichothec-9-ene-3.alpha.,4.beta.,15-triol, 12,13-epoxy-, 15-acetate |
| 15-mas |
| 15-acetoxy-3alpha,4beta-dihydroxy-12,13-epoxytrichothec-9-ene |
| trichothec-9-ene-3alpha,4alpha,4beta)- |
| anguidine, desacetyl(15-acetoxyscirpene-3,4-diol-bl5732) |
| 15-monoacetoxyscirpenol |
| F85597 |
| Class | Description |
|---|---|
| trichothecene | Any one of a large family of chemically related mycotoxins with a structure based on a sesquiterpene skeleton. The most important structural features causing the biological activities of trichothecenes are a 12,13-epoxy ring, the presence of hydroxy or acetyl groups at appropriate positions on the trichothecene nucleus and the structure and position of the side-chain. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||